- The US Anti Cancer Drug Market to Reach USD 134 Billion by 2018. The US anti cancer drug market is expected to be majorly held by the generic drugs
- The sales of anti-cancer drugs has grown at a CAGR of 6.5% in the last 5 years from 2008-2013
- Roche was the market leader in 2013 in the US anti cancer drug market. The major cancer drugs of Roche which contributed towards its revenues were Herceptin, Rituxan and Xeloda.
- The Blood Cancer drug industry sales have been contributing the maximum to the overall sales of anti-cancer drug sales in the US followed by Breast cancer.
Ken Research has
announced the latest market intelligence research report on “The US Anti Cancer Drug Market Outlook to 2018” which provides a comprehensive analysis of US
anti cancer drug industry on the basis of sales, number of cancer drugs
approved and by number of cancer drugs in development. The report includes
coverage on various market segments namely therapies, orals and injectables,
generics and patented drugs. The report also features the company profiles of
major cancer drug manufacturers in the US as well as the revenues of major ten
players in the US Anti Cancer Drug Market.
 |
| The US Anti Cancer Drug Market |
Over the years, the US anti cancer
drug market has developed extensively and has contributed significantly towards
the US’s healthcare segment. The market has registered revenues growth of 6.5%
from 2008 to 2013. The revenues of the market have been derived majorly from
two major cancer drug segments, namely patented and generic drugs.
The US anti cancer drug market is majorly held by the generic
drugs in 2013. The high prices of patented drugs have led to a fall in their
market share over the years. An emerging trend in the US anti cancer drug
market has led to a shift of focus to developing targeted drugs for individual
cases of cancer and the cancer drug makers are now moving towards personalized
healthcare.
The market for anti cancer drugs in the US is highly fragmented,
but is slowly moving towards consolidation with many major pharmaceutical
companies opting for joint ventures and strategic alliances so as to tap newer
markets and to offset the losses incurred by their major drugs going off-patent.
Roche was the major player of this market in 2013.
The US Anti cancer Drug Market is expected to undergo
transformation in the years to come mostly backed by the pharmaceutical
companies moving towards personalized healthcare with innovation so as to bring
better cancer drugs in the future to improve survival rates. Revenues from the
anti cancer drugs market in the US are expected to expand to USD 134 billion in
2018 on account of more number of drugs being approved by the United States
Food and Drug Association and increased expenditure by the government on
healthcare.
Key Topics Covered in the Report:
1.
The US anti cancer drug market
·
Introduction, Industry sales
·
Number of drugs in development
·
Number of drugs approved
·
Number of New Cancer Cases
- Market Segmentation by
·
Oral and Injectables
·
Generic and Patent Drugs
·
Cost of Therapies
- Blood, Breast, Lung, Colon, Pancreatic cancer drug market
- Industry Sales in last 5 years (2008-2013)
- Sales of Major Brands
- Treatment and Side Effect
- Patent and Expiry
- Government Regulations in US Anti Cancer Drug Market.
- SWOT Analysis, Growth Drivers, Restraints
- Future outlook and projections
Major Companies
Mentioned in the Report
Roche
Amgen
Novartis
Celgene
Eli Lilly
Bristol Myers
Pfizer
Merck & Co
Sanofi Aventis
Astra Zeneca
GlaxoSmithKline
Related Reports:
Contact:
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249
Ken Research
Ankur Gupta, Head Marketing & Communications
Ankur@kenresearch.com
+91-9015378249
